Currently, there is a movement from change endpoints to endpoints with absolute values.
Mean (SD) change in the CGI-BP-S and CGI-S scores were reported from the baseline of the original double-blind acute treatment study based on both an observed case (OC) and last observation carried forward to endpoint (LOCF-endpoint) analysis.
aStatistically significant (P ≤ 0.05) within-group change from baseline to endpoint at acute-phase endpoint (week 12).
Furthermore, in all subjects except one, an additional progression was reported running from endpoint 8′ on PT to endpoint 3′ on posterior HG.
Still, 3 of their progressions were observed in all subjects without exception: one running from endpoint 1′ on lateral HG to endpoint 2′ on anteromedial HG; one running from endpoint 1′ on lateral HG to endpoint 3′ on posterior HG; and one running from endpoint 6′ on lateral superior temporal gyrus to endpoint 3′ on posterior HG.
The proportions of responders were calculated for patients with a reduction in the BPI average pain score of ≥30%% from baseline to endpoint or ≥50%% from baseline to endpoint, and also for patients with a sustained response.
As proposed in previous work [43],[44], we transform the numeric endpoint to a binary nominal endpoint.
Will the use of a potential surrogate endpoint to replace the unobserved true endpoint give qualitatively the correct results?
That is, it is something that varies among individuals, for which such variation accounts for the existence of background cases in the absence of exposure, for which small changes are sufficient in at least some individuals to move them from being without the apical endpoint to having the apical endpoint, and for which very small exposures to the chemical will indeed produce those small changes.
Tying this back to the endpoint, the endpoint is poised to become contextual with identities, applications and user behavior patterns, which will drive consolidation within the endpoint, application and security analytics vendors.
